Last reviewed · How we verify
insulin lispro MM
Insulin lispro is a rapid-acting insulin analog that binds to the insulin receptor to promote glucose uptake and utilization in peripheral tissues.
Insulin lispro is a rapid-acting insulin analog that binds to the insulin receptor to promote glucose uptake and utilization in peripheral tissues. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | insulin lispro MM |
|---|---|
| Also known as | Mid Mix, Humalog |
| Sponsor | Eli Lilly and Company |
| Drug class | Rapid-acting insulin analog |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin lispro is a recombinant human insulin analog created by reversing two amino acids (lysine and proline) at positions 28 and 29 of the B chain. This modification reduces self-association and allows faster absorption from subcutaneous injection sites compared to regular human insulin. Once absorbed, it binds to insulin receptors on muscle and adipose tissue to facilitate glucose transport and metabolism, lowering blood glucose levels.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Lipodystrophy
- Weight gain
Key clinical trials
- A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus (PHASE1)
- Study on the Effects on Blood Glucose Following Intradermal and Subcutaneous Dosing of Insulin in Diabetic Patients (PHASE1, PHASE2)
- Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019) (PHASE4)
- Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- insulin lispro MM CI brief — competitive landscape report
- insulin lispro MM updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI